Company news
IDEAYA Biosciences, Inc. news in 2020
IDEAYA Biosciences, Inc.'s news releases, calls and decks from 2020, newest first.
IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index
December 13, 2020
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
November 11, 2020
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
October 21, 2020
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations
September 23, 2020
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
August 11, 2020
IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment
August 3, 2020
IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket Trial
July 15, 2020
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor
July 8, 2020
IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics
June 29, 2020
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
June 15, 2020
IDEAYA Biosciences Selected to Join Russell 3000® Index
June 10, 2020
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
June 7, 2020
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
May 14, 2020
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
May 11, 2020
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team
April 20, 2020
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update
March 23, 2020
IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
March 17, 2020
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities
March 10, 2020
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
January 14, 2020
Decks in 2020
- Investor Presentation (June 2020)
Investor deck · 23 slides · Jun 16, 2020
- JP Morgan Conference January 2020
Conference · 23 slides · Jan 13, 2020